Science

Jul 13, 2025, 13:50

Myeloma Paper of the Day, July 13th, Suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day:

Sequential treatment with two different commercially approved BCMA CAR-T products (ide-cel -> cilta-cel) is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR-T therapy.”

Title: Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma

Authors: Tim Richardson, Udo Holtick, Jan Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias K Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christoph Scheid, Philipp Gödel

You can read the Full Article in Blood Advances.

Myeloma Paper of the Day, July 13th, Suggested by Robert Orlowski

You can find more posts featuring Robert Orlowski in OncoDaily.

BCMA BCMA CAR-T therapy cancer CAR-T Christoph Scheid Elias K. Mai Hishan Tharmaseelan Hyatt Balke-Want Jan Hendrik Frenking Malte von Bonin Michael Hallek MM Myeloma Myeloma Paper of the Day OncoDaily Oncology Philipp Gödel Raphael Teipel refractory multiple myeloma Robert Orlowski Ruth Flümann Sandra Sauer Tim Richardson Udo Holtick

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips

Marty Makary: FDA Has Published More than 200 Complete Response Letters

In Memory of Zelig Eshhar: The Man Who Taught T Cells to Fight Cancer